Article Text
PDFCommentary
Nocebo effects: a price worth paying for full transparency?
Statistics from Altmetric.com
Footnotes
Twitter @brwmcmillan
Funding Brian McMillan and Gail Davidge are funded by an NIHR Advanced Fellowship (NIHR300887).
Disclaimer The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
Linked Articles
Read the full text or download the PDF:
Other content recommended for you
- Sharing online clinical notes with patients: implications for nocebo effects and health equity
- Unethical informed consent caused by overlooking poorly measured nocebo effects
- Response to commentaries on sharing online clinical notes with patients: implications for nocebo effects and health equity
- ‘Scan-negative’ cauda equina syndrome: what to do when there is no neurosurgical cause
- Placebo effects and racial and ethnic health disparities: an unjust and underexplored connection
- The nocebo effect: patient expectations and medication side effects
- Placebo and nocebo effects and mechanisms associated with pharmacological interventions: an umbrella review
- Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar
- Diagnosis of cauda equina syndrome in the emergency department
- Prescribing placebos ethically: the appeal of negatively informed consent